Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Federal University of São Paulo
This clinical study aims to compare the use of the hypotensive eye drop Triplenex, a fixed triple combination (currently available only in Brazil, Mexico, and Chile), with the globally recognized combination of the same drugs administered separately. The combination of the eye drops Bimatoprost 0.3%, Timolol Maleate 0.5%, and Brimonidine Tartrate 0.2% in separate vials is traditionally used in patients with difficult intraocular pressure control or advanced glaucoma that requires a low target pressure for proper disease management. The fixed triple combination intends to improve patient adherence while maintaining the efficacy of intraocular pressure control and progression of glaucoma. This study arises in the context of a lack of literature comparing Triplenex to the three original drugs and the absence of data on its influence on adherence, ocular surface, and the quality of life in the daily lives of glaucoma patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patients with diagnosed glaucoma
above 18 years old
in use of at least 3 different glaucoma eyedrops classes
informed consent form granted
You may not be if
secundary glaucoma
previous ocular surface disease
previous intraocular surgeries (except cataract)
previous ocular trauma
current use of contact lenses use
current use of steroids or systemic medications that may change ocular surface